• Study of Resmetirom in Patients with Well-compensated Non-alcoholic Steatohepatitis (NASH) Cirrhosis to Evaluate Effects on Liver Health

    Not recruiting

    3 1
    Investigated diseases:
    Investigated drugs:
    Belgium France Germany Italy Spain

  • Study on the Safety of ARV-471 and Everolimus for Patients with Advanced or Metastatic ER+, HER2- Breast Cancer

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Spain

  • Study of Debio 4228 for Patients with Advanced or Metastatic Prostate Cancer

    Not recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Bulgaria France Italy Lithuania Poland +1

  • Study of secukinumab and prednisone combination therapy for patients with giant cell arteritis (GCA): Evaluation of treatment effectiveness and safety

    Not recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium Bulgaria Czechia Denmark Estonia +11

  • Study on Tolebrutinib for Patients with Primary Progressive Multiple Sclerosis

    Not recruiting

    3 1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium Bulgaria Croatia Czechia Denmark +13

  • Study on Acalabrutinib, Venetoclax, and Obinutuzumab for Untreated Chronic Lymphocytic Leukemia Patients Without del(17p) or TP53 Mutation

    Not recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Bulgaria Czechia Denmark France Germany +7

  • Study of Pembrolizumab for Patients with Relapsed or Refractory Classical Hodgkin’s Lymphoma or Primary Mediastinal Large B-cell Lymphoma

    Not recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Czechia Italy Poland

  • Study on Palbociclib and Endocrine Therapy for Patients with HR+/HER2- Early Breast Cancer

    Not recruiting

    3 1 1
    Investigated drugs:
    Austria Belgium Germany Hungary Ireland Italy +5

  • Study on Pausing Treatment with Pembrolizumab and Axitinib in Patients with Metastatic Kidney Cancer at Good or Intermediate Risk

    Not recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study of Encorafenib, Cetuximab, and Pembrolizumab for Patients with Untreated BRAF V600E-Mutant Metastatic Colorectal Cancer

    Not recruiting

    2 1 1 1
    Investigated drugs:
    Belgium Czechia Denmark France Germany Italy +6

powered by